Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income: 2014-2024

Historic Net Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$77.4 million.

  • Cartesian Therapeutics' Net Income fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Net Income stood at -$77.4 million for FY2024, which was up 64.76% from -$219.7 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Net Income registered a high of $35.4 million during FY2022, and its lowest value of -$219.7 million during FY2023.
  • Over the past 3 years, Cartesian Therapeutics' median Net Income value was -$77.4 million (recorded in 2024), while the average stood at -$87.3 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Net Income soared by 237.73% in 2022 and then plummeted by 721.02% in 2023.
  • Cartesian Therapeutics' Net Income (Yearly) stood at -$68.9 million in 2020, then spiked by 62.71% to -$25.7 million in 2021, then surged by 237.73% to $35.4 million in 2022, then slumped by 721.02% to -$219.7 million in 2023, then spiked by 64.76% to -$77.4 million in 2024.